The Systemic Lupus Erythematosus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Systemic Lupus Erythematosus Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Systemic Lupus Erythematosus Market.

Some of the key takeaways from the Systemic Lupus Erythematosus Pipeline Report:

• Companies across the globe are diligently working toward developing novel Systemic Lupus Erythematosus treatment therapies with a considerable amount of success over the years. 
• Systemic Lupus Erythematosus companies working in the treatment market are Equillium, Biocon Limited, Kangpu Biopharmaceuticals, Boston Pharmaceuticals, Nektar Therapeutics, AbbVie, Horizon Therapeutics, Sanofi, Biogen, Hoffman-La-Roche, and others, are developing therapies for the Systemic Lupus Erythematosus treatment 

• Emerging Systemic Lupus Erythematosus therapies in the different phases of clinical trials are- Mosunetuzumab, Itolizumab, KPG 818, BOS161721, NKTR-358, ABBV-599, Daxdilimab (VIB7734), SAR441344, BIIB059, Obinutuzumab, and others are expected to have a significant impact on the Systemic Lupus Erythematosus market in the coming years.   
• In October 2023, AbbVie revealed a partnership with Lupus Therapeutics aimed at enhancing the recruitment efforts for its systemic lupus erythematosus (SLE) trial. The collaboration specifically targets the Phase III clinical initiative for AbbVie’s upadacitinib (RINVOQ) among SLE patients. Within this partnership, Lupus Therapeutics will provide support to AbbVie in recruiting trial participants and facilitating the activation and involvement of trial sites through the Lupus Clinical Investigators Network (LuCIN).
• In February 2022, The National Medical Products Administration (NMPA) of China granted approval to GlaxoSmithKline’s Benlysta for the treatment of active lupus nephritis (LN) in adult patients within China.
• In February 2022, AstraZeneca’s Saphnelo (anifrolumab) received approval in the European Union as an additional therapy for the treatment of adult patients diagnosed with moderate to severe, active systemic lupus erythematosus (SLE) and who test positive for autoantibodies, despite already undergoing standard treatment.

Systemic Lupus Erythematosus Overview

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that can affect various parts of the body. In this condition, the immune system mistakenly attacks healthy tissues and organs, leading to inflammation, pain, and damage to different systems within the body.

Get a Free Sample PDF Report to know more about Systemic Lupus Erythematosus Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-pipeline-insight

Emerging Systemic Lupus Erythematosus Drugs Under Different Phases of Clinical Development Include:

• Mosunetuzumab: Roche
• Itolizumab: Equillium/ Biocon Limited
• KPG 818: Kangpu Biopharmaceuticals
• BOS161721: Boston Pharmaceuticals S
• NKTR-358: Nektar Therapeutics
• ABBV-599: AbbVie
• Daxdilimab (VIB7734): Horizon Therapeutics
• SAR441344: Sanofi
• BIIB059: Biogen
• Obinutuzumab: Hoffman-La-Roche

Systemic Lupus Erythematosus Route of Administration

Systemic Lupus Erythematosus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Systemic Lupus Erythematosus Molecule Type

Systemic Lupus Erythematosus Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Systemic Lupus Erythematosus Pipeline Therapeutics Assessment

• Systemic Lupus Erythematosus Assessment by Product Type
• Systemic Lupus Erythematosus By Stage and Product Type
• Systemic Lupus Erythematosus Assessment by Route of Administration
• Systemic Lupus Erythematosus By Stage and Route of Administration
• Systemic Lupus Erythematosus Assessment by Molecule Type
• Systemic Lupus Erythematosus by Stage and Molecule Type

DelveInsight’s Systemic Lupus Erythematosus Report covers around 60+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Systemic Lupus Erythematosus product details are provided in the report. Download the Systemic Lupus Erythematosus pipeline report to learn more about the emerging Systemic Lupus Erythematosus therapies

Some of the key companies in the Systemic Lupus Erythematosus Therapeutics Market include:

Key companies developing therapies for Systemic Lupus Erythematosus are – Sanofi SA, Eli Lilly & Company, Viatris Inc., Novartis AG, GlaxoSmithKline, F. Hoffmann-La Roche AG, Pfizer Limited, ImmuPharma PLC, Bristl Myers Squibb Company, AstraZeneca, Merck & Co., Inc., and others.

Systemic Lupus Erythematosus Pipeline Analysis:

The Systemic Lupus Erythematosus pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Systemic Lupus Erythematosus with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Systemic Lupus Erythematosus Treatment.
• Systemic Lupus Erythematosus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Systemic Lupus Erythematosus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Systemic Lupus Erythematosus market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Systemic Lupus Erythematosus drugs and therapies

Systemic Lupus Erythematosus Pipeline Market Drivers

• Promising Therapeutic Approaches, increasing Awareness of the Disease, recent Advancements in Research and Development are some of the important factors that are fueling the Systemic Lupus Erythematosus Market.

Systemic Lupus Erythematosus Pipeline Market Barriers

• However, obstacles in Systemic Lupus Erythematosus Pipeline, hit and Trial Approach of Researchers, high Annual Cost of Therapies and other factors are creating obstacles in the Systemic Lupus Erythematosus Market growth.

Scope of Systemic Lupus Erythematosus Pipeline Drug Insight    

• Coverage: Global
• Key Systemic Lupus Erythematosus Companies: Equillium, Biocon Limited, Kangpu Biopharmaceuticals, Boston Pharmaceuticals, Nektar Therapeutics, AbbVie, Horizon Therapeutics, Sanofi, Biogen, Hoffman-La-Roche, and others
• Key Systemic Lupus Erythematosus Therapies: Mosunetuzumab, Itolizumab, KPG 818, BOS161721, NKTR-358, ABBV-599, Daxdilimab (VIB7734), SAR441344, BIIB059, Obinutuzumab, and others
• Systemic Lupus Erythematosus Therapeutic Assessment: Systemic Lupus Erythematosus current marketed and Systemic Lupus Erythematosus emerging therapies
• Systemic Lupus Erythematosus Market Dynamics: Systemic Lupus Erythematosus market drivers and Systemic Lupus Erythematosus market barriers 

Request for Sample PDF Report for Systemic Lupus Erythematosus Pipeline Assessment and clinical trials

Table of Contents

1. Systemic Lupus Erythematosus Report Introduction

2. Systemic Lupus Erythematosus Executive Summary

3. Systemic Lupus Erythematosus Overview

4. Systemic Lupus Erythematosus- Analytical Perspective In-depth Commercial Assessment

5. Systemic Lupus Erythematosus Pipeline Therapeutics

6. Systemic Lupus Erythematosus Late Stage Products (Phase II/III)

7. Systemic Lupus Erythematosus Mid Stage Products (Phase II)

8. Systemic Lupus Erythematosus Early Stage Products (Phase I)

9. Systemic Lupus Erythematosus Preclinical Stage Products

10. Systemic Lupus Erythematosus Therapeutics Assessment

11. Systemic Lupus Erythematosus Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Systemic Lupus Erythematosus Key Companies

14. Systemic Lupus Erythematosus Key Products

15. Systemic Lupus Erythematosus Unmet Needs

16 . Systemic Lupus Erythematosus Market Drivers and Barriers

17. Systemic Lupus Erythematosus Future Perspectives and Conclusion

18. Systemic Lupus Erythematosus Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/